ES2117155T3 - Nuevas 3,3-difenilpropilaminas, su uso y su preparacion. - Google Patents

Nuevas 3,3-difenilpropilaminas, su uso y su preparacion.

Info

Publication number
ES2117155T3
ES2117155T3 ES93924876T ES93924876T ES2117155T3 ES 2117155 T3 ES2117155 T3 ES 2117155T3 ES 93924876 T ES93924876 T ES 93924876T ES 93924876 T ES93924876 T ES 93924876T ES 2117155 T3 ES2117155 T3 ES 2117155T3
Authority
ES
Spain
Prior art keywords
compounds
preparation
methyl
formula
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93924876T
Other languages
English (en)
Inventor
Rolf Arne Johansson
Pinchas Moses
Lisbeth Nilverbant
Bengt Ake Sparf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20387730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2117155(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2117155T3 publication Critical patent/ES2117155T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

LA INVENCION SE REFIERE A 3,3-DIFENILOPROPILAMINAS DE LA FORMULA (I), EN LA QUE R1 SIGNIFICA HIDROGENO O METILO, R2 Y R3 SIGNIFICAN INDEPENDIENTEMENTE HIDROGENO, METILO, METOXI, HIDROXI, CARBAMOILO, SULFAMOILO O HALOGENO, Y X REPRESENTA UN GRUPO AMINO TERCIARIO DE LA FORMULA (II), EN LA QUE R4 Y R5 SIGNIFICAN GRUPOS HIDROCARBILO NO AROMATICOS, LOS CUALES PUEDEN SER IGUALES O DIFERENTES Y LOS CUALES JUNTOS CONTIENEN POR LO MENOS TRES ATOMOS DE CARBONO, Y EN LA QUE R4 Y R5 PUEDEN FORMAR UN ANILLO JUNTO CON EL NITROGENO AMINO, SUS SALES CON ACIDOS FISIOLOGICAMENTE ACEPTABLES, CUANDO LOS COMPUESTOS PUEDEN ESTAR EN FORMA DE ISOMEROS OPTICOS, LA MEZCLA RACEMICA Y LOS ENANTIOMEROS INDIVIDUALES. LA INVENCION TAMBIEN SE REFIERE A METODOS PARA SU PREPARACION, A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS NUEVOS COMPUESTOS, Y AL USO DE LOS COMPUESTOS PARA PREPARAR MEDICAMENTOS.
ES93924876T 1992-11-06 1993-11-05 Nuevas 3,3-difenilpropilaminas, su uso y su preparacion. Expired - Lifetime ES2117155T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9203318A SE9203318D0 (sv) 1992-11-06 1992-11-06 Novel 3,3-diphenylpropylamines, their use and preparation

Publications (1)

Publication Number Publication Date
ES2117155T3 true ES2117155T3 (es) 1998-08-01

Family

ID=20387730

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93924876T Expired - Lifetime ES2117155T3 (es) 1992-11-06 1993-11-05 Nuevas 3,3-difenilpropilaminas, su uso y su preparacion.

Country Status (14)

Country Link
US (4) USRE40851E1 (es)
EP (1) EP0667852B1 (es)
JP (1) JP3343256B2 (es)
AT (1) ATE164828T1 (es)
AU (1) AU672458B2 (es)
CA (1) CA2148827C (es)
DE (1) DE69317898T2 (es)
DK (1) DK0667852T3 (es)
ES (1) ES2117155T3 (es)
FI (1) FI120256B (es)
HU (1) HU224916B1 (es)
NO (1) NO305477B1 (es)
SE (1) SE9203318D0 (es)
WO (1) WO1994011337A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
WO1998000140A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r)-trihexyphenidyl
JP4167302B2 (ja) * 1996-12-02 2008-10-15 杏林製薬株式会社 新規ｎ―置換ピロリジン誘導体及びその製造法
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
CA2311755C (en) 1998-08-27 2010-03-23 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
MXPA02004574A (es) 1999-11-11 2004-09-10 Pharmacia Ab Formulacion farmaceutica que contiene tolterodina y su uso.
DE29923134U1 (de) 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
US6790854B2 (en) 2000-03-24 2004-09-14 Meiji Seika Kaisha, Ltd. Diphenylalkylamine derivatives useful as opioid receptor agonists
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
CN1536986B (zh) * 2001-03-27 2012-07-04 沃纳奇尔科特(爱尔兰)有限公司 用于抗微生物剂给药的阴道内药物递送装置
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
EP1461306B1 (en) * 2001-10-26 2008-12-24 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds and their use as antimuscarinic agents
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
MXPA04003866A (es) * 2001-11-09 2004-07-08 Pharmacia Ab Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
DE60230683D1 (de) * 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
MXPA05004754A (es) 2002-11-13 2005-08-02 Chiron Corp Metodos para tratar cancer y metodos relacionados.
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US7517905B2 (en) * 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2522071A1 (en) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
MXPA05011509A (es) 2003-04-25 2005-12-15 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) sustituidas con halogenos que presentan actividad antimuscarinica.
EP1633695B1 (en) * 2003-05-23 2012-02-15 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
US7538249B2 (en) * 2003-12-24 2009-05-26 Cipla Limited Tolterodine, compositions and uses thereof, and preparation of the same
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US20100035954A1 (en) * 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists
WO2006074479A1 (en) * 2005-01-10 2006-07-13 Teva Pharmaceutical Industries, Ltd. Process for preparing tolterodine tartrate
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
CN101222850B (zh) 2005-05-13 2012-10-03 诺瓦提斯公司 治疗对药物有抗性的癌症的方法
WO2007072169A2 (en) * 2005-12-20 2007-06-28 Pfizer Products Inc. Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
EA016203B1 (ru) 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
JP5257353B2 (ja) * 2006-05-31 2013-08-07 シュウォーツ ファーマ リミテッド 置換ヒドロキシメチルフェノールの新規な合成
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
DE602007008389D1 (de) 2006-06-09 2010-09-23 Schwarz Pharma Ltd Synthese von phenolischen estern von hydroxymethylphenolen
WO2007144097A1 (en) 2006-06-12 2007-12-21 Schwarz Pharma Ag New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
EP2044001B1 (en) 2006-06-20 2016-11-23 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-n-alkyl-3-phenylpropylamines
US20100217034A1 (en) * 2007-09-21 2010-08-26 Actavis Group Ptc Ehf Process for the Preparation of Fesoterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
BRPI1010820A2 (pt) * 2009-05-11 2019-09-24 Ratiopharm Gmbh desfesoterodina na forma de um sal de acido tartarico
IT1394219B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
IT1394217B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
SI2281801T1 (sl) 2009-07-27 2014-04-30 Crystal Pharma, S.A.U. Postopek za pridobivanje 3,3-diphenilpropilamina
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2364966A1 (en) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
JP6234999B2 (ja) 2012-05-04 2017-11-22 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． 光学的に活性な３，３−ジフェニルプロピルアミンを調製するための方法
PL2760822T3 (pl) 2012-06-14 2016-09-30 Sole desfezoterodyny
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2016148444A1 (ko) * 2015-03-17 2016-09-22 제이더블유중외제약 주식회사 신규 데스페소테로딘 유도체, 이의 약제학적으로 허용되는 염 및 이를 포함하는 약제학적 조성물
WO2017137955A1 (en) 2016-02-14 2017-08-17 Celestis Pharmaceuticals Pvt. Ltd. Novel (r) and rac 3-(2-(allyloxy)-5-methylphenyl)-n,n-diisopropyl-3- phenylpropan-1-amine and its use for synthesis of (r) and rac-2-(3- (diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111894A (es) 1962-11-15
GB1169944A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
GB1169945A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
US4139537A (en) 1976-06-29 1979-02-13 Cooper Laboratories, Inc. 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
JPH08503208A (ja) 1996-04-09
FI120256B (fi) 2009-08-31
SE9203318D0 (sv) 1992-11-06
NO951775D0 (no) 1995-05-05
CA2148827A1 (en) 1994-05-26
US5686464A (en) 1997-11-11
JP3343256B2 (ja) 2002-11-11
USRE39667E1 (en) 2007-05-29
AU672458B2 (en) 1996-10-03
EP0667852A1 (en) 1995-08-23
HU9501329D0 (en) 1995-06-28
EP0667852B1 (en) 1998-04-08
FI952179A0 (fi) 1995-05-05
USRE40851E1 (en) 2009-07-14
ATE164828T1 (de) 1998-04-15
HU224916B1 (en) 2006-04-28
DE69317898D1 (de) 1998-05-14
HK1006349A1 (en) 1999-02-19
CA2148827C (en) 2005-01-04
NO951775L (no) 1995-05-05
HUT72742A (en) 1996-05-28
WO1994011337A1 (en) 1994-05-26
DK0667852T3 (da) 1999-01-11
FI952179A7 (fi) 1995-05-05
US5559269A (en) 1996-09-24
NO305477B1 (no) 1999-06-07
AU5438094A (en) 1994-06-08
DE69317898T2 (de) 1998-10-15

Similar Documents

Publication Publication Date Title
ES2117155T3 (es) Nuevas 3,3-difenilpropilaminas, su uso y su preparacion.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ES2029384T3 (es) Procedimiento para preparar nuevas 3,3-difenilpropilaminas.
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
AR023289A1 (es) COMPUESTOS CON ACTIVIDAD INHIBIDORA DE ENDOPEPTIDASA NEUTRA (NEP), COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y PROCEDIMIENTO PARA SU PREPARACIoN.
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
BR9812428A (pt) Compostos oxo-substituìdos, processo de preparo, e composições e métodos para inibir a atividade de parp
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
ES2036213T3 (es) Procedimiento para preparar derivados tetrahidroisoquinolin-1-ilicos de acidos carboxilicos.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
MX9401080A (es) Compuestos heteroaromaticos.
DK0553016T3 (da) Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem
ES2102870T3 (es) Benzopiranos y composiciones farmaceuticas que los contienen.
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2060592T3 (es) Un tioester y su uso en la preparacion de composiciones farmaceuticas para el tratamiento de los sindromes de isquemia y reperfusion.
ES2182090T3 (es) Nuevos derivados de pirrol.
ES2064361T3 (es) Nuevos compuestos.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES2055138T3 (es) Procedimiento de preparacion de nuevos derivados del benceno.
ES2077473T3 (es) Nuevos compuestos tiocromanicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2054980T3 (es) Compuestos para el tratamiento de la incontinencia urinaria.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 667852

Country of ref document: ES